Passage Bio (PASG) FDA Approvals $3.98 -0.16 (-3.74%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings Passage Bio's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Passage Bio (PASG). Over the past two years, Passage Bio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PBFT02. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. PBFT02 FDA Regulatory Timeline and Events PBFT02 is a drug developed by Passage Bio for the following indication: Dementia with granulin mutations (FTD-GRN). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Updated data - April 20,2026Updated Data Phase 1/2Drug: PBFT02Announced Date: April 20, 2026Indication: Dementia with granulin mutations (FTD-GRN)AnnouncementPassage Bio, Inc. reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations.AI SummaryPassage Bio reported updated interim data from the ongoing Phase 1/2 upliFT-D trial of PBFT02 in frontotemporal dementia caused by GRN mutations (FTD‑GRN). In patients with baseline global CDR=1 who received PBFT02, whole brain atrophy at 12 months averaged 3.1% versus 8.7% in an untreated ALLFTD natural history group (n=2 treated vs n=7 natural history), a 64% relative reduction. Frontotemporal cortex atrophy averaged 4.6% versus 9.9% in the natural history sample, a 54% relative reduction. Plasma neurofilament light (NfL) stabilized in treated patients: PBFT02 recipients showed an average 1.0 pg/mL decrease at 12 months (n=6), while untreated symptomatic FTD‑GRN patients in ALLFTD rose by 13.5 pg/mL (n=7). Passage Bio also reported CSF progranulin and safety data (safety cohort: n=10 FTD‑GRN and n=1 FTD‑C9orf72). Sample sizes are small and comparisons use natural history data, so results are preliminary.Read AnnouncementUpdated data - June 23,2025Updated Data Phase 1/2Drug: PBFT02Announced Date: June 23, 2025Indication: Dementia with granulin mutations (FTD-GRN)AnnouncementPassage Bio, Inc. today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and provided program updates and anticipated milestones.AI SummaryPassage Bio, Inc. has shared promising updated data from its ongoing Phase 1/2 upliFT-D clinical trial that is evaluating PBFT02 for treating frontotemporal dementia (FTD) with GRN mutations. The results show that PBFT02 consistently raises CSF progranulin (PGRN) levels in a durable manner over 18 months and slows the rise of plasma neurofilament light (NfL) levels compared to natural disease progression. Notably, a lower Dose 2 (50% of Dose 1) significantly increased CSF PGRN, nearing healthy adult levels. The company is adjusting the trial protocol by introducing a short course of low dose prophylactic anticoagulation and modifying inclusion criteria to enroll patients at an earlier stage of disease. Passage Bio is on track to seek regulatory feedback on the design of its pivotal trial for FTD-GRN in the first half of 2026.Read AnnouncementUpdated data - January 10,2025Updated Data Phase 1/2Drug: PBFT02Announced Date: January 10, 2025Indication: Dementia with granulin mutations (FTD-GRN)AnnouncementPassage Bio, Inc. today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and anticipated upcoming milestones.AI SummaryPassage Bio, Inc. reported updated interim data from its ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for treating frontotemporal dementia (FTD) with granulin (GRN) mutations. The trial demonstrated that Dose 1 of PBFT02 produced a durable increase in cerebrospinal fluid PGRN levels and early indications of reduced plasma NfL levels, a biomarker associated with disease progression, when compared to published natural history data. The company is introducing Dose 2, which is 50% lower than Dose 1, to explore optimal dosing in FTD-GRN and FTD-C9orf72 patients and support its regulatory strategy. Passage Bio plans to report 12-month data from Dose 1 along with interim safety and biomarker data from Dose 2 in the second half of 2025, and it aims to seek regulatory feedback on the registrational trial design in the first half of 2026.Read Announcement Passage Bio FDA Events - Frequently Asked Questions Has Passage Bio received FDA approval? As of now, Passage Bio (PASG) has not received any FDA approvals for its therapy in the last two years. What drugs has Passage Bio submitted to the FDA? In the past two years, Passage Bio (PASG) has reported FDA regulatory activity for PBFT02. What is the most recent FDA event for Passage Bio? The most recent FDA-related event for Passage Bio occurred on April 20, 2026, involving PBFT02. The update was categorized as "Updated data," with the company reporting: "Passage Bio, Inc. reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations." What conditions do Passage Bio's current drugs treat? Currently, Passage Bio has one therapy (PBFT02) targeting the following condition: Dementia with granulin mutations (FTD-GRN). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagene FDA EventsAlnylam Pharmaceuticals FDA EventsGE HealthCare Technologies FDA EventsGenprex FDA EventsHUTCHMED FDA EventsOpus Genetics FDA EventsLigand Pharmaceuticals FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsRegeneron Pharmaceuticals FDA EventsTvardi Therapeutics FDA EventsBiohaven FDA EventsJohnson & Johnson FDA EventsActuate Therapeutics FDA EventsEnlivex Therapeutics FDA EventsImmuneering FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Pliant Therapeutics FDA Events Mereo BioPharma Group FDA Events Werewolf Therapeutics FDA Events Gain Therapeutics FDA Events Kalaris Therapeutics FDA Events Caribou Biosciences FDA Events Instil Bio FDA Events Connect Biopharma FDA Events Biomea Fusion FDA Events Estrella Immunopharma FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:PASG last updated on 4/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Updated data - April 20,2026Updated Data Phase 1/2Drug: PBFT02Announced Date: April 20, 2026Indication: Dementia with granulin mutations (FTD-GRN)AnnouncementPassage Bio, Inc. reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations.AI SummaryPassage Bio reported updated interim data from the ongoing Phase 1/2 upliFT-D trial of PBFT02 in frontotemporal dementia caused by GRN mutations (FTD‑GRN). In patients with baseline global CDR=1 who received PBFT02, whole brain atrophy at 12 months averaged 3.1% versus 8.7% in an untreated ALLFTD natural history group (n=2 treated vs n=7 natural history), a 64% relative reduction. Frontotemporal cortex atrophy averaged 4.6% versus 9.9% in the natural history sample, a 54% relative reduction. Plasma neurofilament light (NfL) stabilized in treated patients: PBFT02 recipients showed an average 1.0 pg/mL decrease at 12 months (n=6), while untreated symptomatic FTD‑GRN patients in ALLFTD rose by 13.5 pg/mL (n=7). Passage Bio also reported CSF progranulin and safety data (safety cohort: n=10 FTD‑GRN and n=1 FTD‑C9orf72). Sample sizes are small and comparisons use natural history data, so results are preliminary.Read Announcement
Updated data - June 23,2025Updated Data Phase 1/2Drug: PBFT02Announced Date: June 23, 2025Indication: Dementia with granulin mutations (FTD-GRN)AnnouncementPassage Bio, Inc. today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and provided program updates and anticipated milestones.AI SummaryPassage Bio, Inc. has shared promising updated data from its ongoing Phase 1/2 upliFT-D clinical trial that is evaluating PBFT02 for treating frontotemporal dementia (FTD) with GRN mutations. The results show that PBFT02 consistently raises CSF progranulin (PGRN) levels in a durable manner over 18 months and slows the rise of plasma neurofilament light (NfL) levels compared to natural disease progression. Notably, a lower Dose 2 (50% of Dose 1) significantly increased CSF PGRN, nearing healthy adult levels. The company is adjusting the trial protocol by introducing a short course of low dose prophylactic anticoagulation and modifying inclusion criteria to enroll patients at an earlier stage of disease. Passage Bio is on track to seek regulatory feedback on the design of its pivotal trial for FTD-GRN in the first half of 2026.Read Announcement
Updated data - January 10,2025Updated Data Phase 1/2Drug: PBFT02Announced Date: January 10, 2025Indication: Dementia with granulin mutations (FTD-GRN)AnnouncementPassage Bio, Inc. today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and anticipated upcoming milestones.AI SummaryPassage Bio, Inc. reported updated interim data from its ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for treating frontotemporal dementia (FTD) with granulin (GRN) mutations. The trial demonstrated that Dose 1 of PBFT02 produced a durable increase in cerebrospinal fluid PGRN levels and early indications of reduced plasma NfL levels, a biomarker associated with disease progression, when compared to published natural history data. The company is introducing Dose 2, which is 50% lower than Dose 1, to explore optimal dosing in FTD-GRN and FTD-C9orf72 patients and support its regulatory strategy. Passage Bio plans to report 12-month data from Dose 1 along with interim safety and biomarker data from Dose 2 in the second half of 2025, and it aims to seek regulatory feedback on the registrational trial design in the first half of 2026.Read Announcement